Search
Cephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Pregabalin
go.drugbank.com/drugs/DB00230ApprovedInvestigational[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.[A31161] … [A187190,L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).
Azlocillin
go.drugbank.com/drugs/DB01061ApprovedAzlocillin is a semisynthetic ampicillin-derived acylureido penicillin.
Isavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalFollowing administration, isavuconazonium undergoes biotransformation to form the active moiety, isavuconazole, for the antifungal actions. … It is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane synthesis.
Methocarbamol
go.drugbank.com/drugs/DB00423ApprovedInvestigationalVet approved[L6295] A combination product with [acetylsalicylic acid] and [codeine] is available in Canada by prescription.[L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265]
Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalIt has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
BLX-883
go.drugbank.com/drugs/DB05904InvestigationalBLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C.
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by … [A218041] Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.[L15516]
Isoeugenol
go.drugbank.com/drugs/DB14188ApprovedIt is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278].
Vosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development … [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention